Henry M. Jackson Foundation
Henry M. Jackson Foundation (HJF) is a 501(c)(3) nonprofit, founded in 1983 and based in Bethesda, Maryland, that provides scientific, administrative, and program operations support for U.S. military medical research, licenses military-derived medical technologies, and operates the HJF Innovation Labs incubator for dual-use biotech startups serving active-duty military, veterans, and civilians.
- Company typePrivate
- Founded1983
- HeadquartersBethesda, United States
- Headcount1,001–5,000
- GTM typeB2B
- OfferingServices
What Henry M. Jackson Foundation does
The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF) is a private 501(c)(3) nonprofit founded in 1983 and headquartered in Bethesda, Maryland, with a workforce of 1,001-5,000. HJF provides scientific, administrative, and program operations services that enable medical research for the U.S. Department of Defense, the Uniformed Services University of the Health Sciences (USU), Walter Reed, the Walter Reed Army Institute of Research (WRAIR), the U.S. Army Military Operational Medicine Research Program, AFRIMS, NIAID, and collaborating academic medical centers. Its core services span proposal support, program operations, regulatory compliance, research administration, and research staffing, funded primarily through federal grants, cooperative agreements, and contracts. HJF serves active-duty military, veterans, their families, and civilians by translating military medical research into diagnostics, therapeutics, vaccines, and operational health frameworks.
HJF also operates a technology licensing platform (innovations.hjf.org) and the HJF Innovation Labs incubator in North Bethesda, Maryland, which was opened in March 2026 in partnership with Montgomery County. Its licensable portfolio spans predictive clinical tools (e.g., the WounDx Clinical Decision Support Tool for wound closure probability), diagnostics and therapeutics for ovarian cancer and acute myeloid leukemia, vaccine candidates for malaria, SARS-CoV-2, fentanyl, and pan-coronavirus targets built on a bacterial ferritin nanoparticle platform, and cross-sarbecovirus neutralizing antibodies. Multiple patents are granted or pending across the U.S., EU, UK, France, Germany, Japan, India, Canada, and Australia. The organization is led by President and CEO Joseph Caravalho, Jr., M.D.
Revenue mechanics combine federal research funding (DoD, USU, NIAID) and royalty/license income from its IP portfolio. HJF's GTM is relationship-led and institution-centric, relying on long-standing partnerships with DoD agencies and academic centers, supplemented by licensing to commercial partners and a growing startup incubation channel through HJF Innovation Labs. Brand visibility is reinforced through the annual Heroes of Military Medicine Awards, held in San Antonio and Washington D.C.
Henry M. Jackson Foundation firmographics
Firmographics- Name
- Henry M. Jackson Foundation
- Legal name
- The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
- Website
- https://hjf.org
- Company type
- Private
- Founded year
- 1983
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- Henry M. Jackson Foundation (HJF) is a 501(c)(3) nonprofit, founded in 1983 and based in Bethesda, Maryland, that provides scientific, administrative, and program operations support for U.S. military medical research, licenses military-derived medical technologies, and operates the HJF Innovation Labs incubator for dual-use biotech startups serving active-duty military, veterans, and civilians.
- Ownership category
- akta.pro rank
Henry M. Jackson Foundation industry classification
Industry- Product category
- Military Medical Research Services
- NAICS
- Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Defense R&D, Test, Evaluation & Innovation (BPAIAHAC)
- akta.pro secondary industry
- Lab Data Exchange & Interoperability (HL7/FHIR/LDT Results Delivery) (HLACAMAL)
Keywords
Where Henry M. Jackson Foundation is headquartered
LocationHeadquarters
- HQ city
- Bethesda
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Henry M. Jackson Foundation business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure, Others
Revenue model
- Research Support Services: HJF provides scientific, administrative, and program operations services to enable medical researchers and clinicians to make discoveries. Revenue comes from grants, cooperative agreements, and service contracts with federal agencies, primarily the Department of Defense.
- Technology Licensing: HJF licenses its proprietary medical technologies including vaccines, therapeutics, and diagnostics to commercial partners for further development and commercialization.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Henry M. Jackson Foundation product offering
Product offeringCore offering
HJF provides scientific, administrative, and program operations services to enable military medical researchers and clinicians to make discoveries, including proposal support, program operations, regulatory compliance, research administration, and research staffing. It also develops and licenses proprietary medical innovations — vaccines, therapeutics, diagnostics, biomarkers, and clinical decision support tools — generated through its military medical research collaborations, and operates a regional biotech incubator for dual-use startups.
Product overview
The Henry M. Jackson Foundation for the Advancement of Military Medicine (HJF) operates as a global nonprofit organization advancing military medicine through a multi-faceted portfolio. HJF provides research solutions services including proposal support, program operations, regulatory compliance, and research staffing. The organization manages the HJF Innovation Labs, a regional biotech incubator in North Bethesda, Maryland for dual-use medical technologies, and the HJF Innovations Technology Platform for licensing military medical innovations. Core licensable technologies include WounDx for wound closure prediction, cancer diagnostics and therapeutics, vaccine candidates including malaria and fentanyl vaccines, and various biomarkers for cancer, infectious diseases, and trauma applications.
Differentiator
Problem solved
Functional benefit
Products and services
- Research Solutions Services Comprehensive research administration services including Proposal Support, Program Operations, Regulatory Compliance, Research Administration, and Research Staffing provided to federal agencies, military commands, and academic medical institutions conducting military medical research.
- HJF Innovation Labs Co-branded regional biotech incubator providing small-scale lab space, shared equipment, wraparound services, and access to global resources including clinical trial sites for early-stage startups developing dual-use military and civilian medical technologies.
- HJF Innovations Technology Platform Online technology licensing and commercialization platform cataloging licensable medical technologies including diagnostics, therapeutics, vaccines, biomarkers, and research tools developed through military medical research.
- WounDx - Predictive Tool on Probability of Successful Wound Closure (HJF 637-22) Clinical Decision Support Tool that analyzes wound healing immune response through cytokine biomarker analysis to predict probability of successful wound closure and reduce dehiscence risk in combat and civilian trauma wounds.
- Diagnostic Tool for High-grade Serous Ovarian Cancer (HJF 616-21) Companion clinical diagnostic assay using orthogonal protein and transcript-based biomarkers correlating with Homologous Recombination Deficiency to prioritize high-grade serous ovarian cancer patients for targeted DNA damage response therapies.
- Small Molecule Therapeutics for Acute Myeloid Leukemia and Solid Tumors (HJF 490-17) Two families of small molecule compounds that specifically block the SETBP1-XPO1 interaction to inhibit tumor cell growth and induce tumor cell differentiation in AML and solid tumors with SETBP1 overexpression or activating mutation.
- Malaria Vaccine (HJF 474-17) Novel malaria vaccine composition containing Plasmodium falciparum circumsporozoite protein immunogen FMP013 formulated with the patented adjuvant ALFQ, with Phase I clinical study demonstrating safety and efficacy.
- Cross-Sarbecovirus Neutralizing Monoclonal Antibodies (HJF 660-23) Six neutralizing monoclonal antibodies with broad sarbecovirus cross-reactivity, intended for developing next-generation vaccine candidates against SARS-CoV-2 and related sarbecoviruses.
- Ly6 Targeted Cancer Immunotherapy (HJF 649-23) Antibodies, antibody-drug conjugates, and CAR transduced immune cells targeting Ly6 family proteins overexpressed in cancer cells.
- Novel Vaccine Enhancers (HJF 642-23) mRNA vaccine improvements that code for antigens and NK cell inhibitors to enhance vaccine durability and reduce side effects.
- Vaccines Against Fentanyl and Fentanyl Analogs (HJF 561-19) Novel fentanyl hapten compounds that induce antibodies with cross-reactivity for fentanyl and fentanyl derivatives.
- Ferritin Nanoparticle Vaccine Platform (HJF 569-20 and HJF 635-22) Bacterial ferritin nanoparticle-based vaccine platform enabling pan-coronavirus vaccines with broad immune responses.
- Peptide Vaccine for Ovarian/Endometrial Cancer (HJF 593-21) Peptide vaccine platform targeting ovarian and endometrial cancer, protected by issued U.S. and European patents.
- Complex Natural Homogenates (HJF 357-13) Worm homogenate compositions for treating allergies and autoimmune diseases, protected by issued patents in multiple jurisdictions.
- Radiation-Protected Protein Compositions (HJF 165-07) Radiation-protected protein compositions protected by seventeen issued patents across multiple jurisdictions, intended to confer protection against radiation exposure.
Quantifiable outcome
- $2 million research award for musculoskeletal injury recovery projects (September 2023 - September 2026)
Companies that use Henry M. Jackson Foundation
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles3 records
Henry M. Jackson Foundation technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration6 records
AI capability14 records
Feature9 records
Henry M. Jackson Foundation partnerships and signals
Strategic signalPartnerships
15 partnerships are on record, tiered core and major.
- Uniformed Services University of the Health Sciences (USU)coreLong-standing partnership for collaborative medical research, technology development, and support for military medicine researchers and clinicians.
- Walter Reed Army Institute of Research (WRAIR)coreCollaborative research on vaccines, therapeutics, and infectious diseases affecting military personnel.
- U.S. Department of DefensecorePrimary funding source and research partner for military medicine advancement through various DoD programs and initiatives.
- U.S. Army Military Operational Medicine Research Program (MOMRP)coreCollaboration on musculoskeletal injury recovery and operational medicine research for Service Members.
- Inova Fairfax Hospital (IFH)majorCollaborative research on diagnostic tools for ovarian cancer and cancer biomarkers.
- Peter MacCallum Cancer Centre (PMCC)majorInternational collaboration on cancer research and biomarker development for ovarian cancer diagnostics.
- Montgomery County GovernmentmajorCo-branded regional biotech incubator (HJF Innovation Labs) for startups developing dual-use military and civilian medical technologies in North Bethesda.
- Duke UniversitymajorCollaborative research on predicting pulmonary complications following rib fractures using machine learning and biomarkers.
- Oregon Health & Science UniversitymajorCollaboration on ERG oncoprotein inhibitors and small molecule therapeutics research.
- Leidos Biomedical Research, Inc.majorCollaboration on mRNA vaccine enhancers and novel vaccine development technologies.
- National Institute of Allergy and Infectious Diseases (NIAID)coreCollaboration on filarial disease research, vaccine candidates, and infectious disease therapeutics.
- Beth Israel Deaconess Medical Center (BIDMC)majorCollaboration on ZIKV and DENV neutralizing antibody research and flavivirus vaccine development.
- Armed Forces Research Institute of Medical Sciences (AFRIMS)majorCollaboration on flavivirus research and neutralizing antibody identification.
- Boston Children's HospitalmajorCollaboration on prostate cancer gene profiles and racial/ethnic biomarker research.
- University of Maryland, Baltimore (UMB)majorCollaboration on shark-derived antibodies and nanobodies for SARS-CoV-2 therapeutics and diagnostics.
Scale indicators2 records
Recent moves7 records
Expansion highlights5 records
Henry M. Jackson Foundation competitors and assessment
Company assessmentDirect peers
- Battelle Memorial Institute: Large nonprofit scientific research organization managing major federal labs and conducting life sciences, biomedical, and defense research for government clients. Operates under a comparable nonprofit, mission-driven model and contract-research structure as HJF.
- RTI International: Nonprofit research institute delivering scientific, statistical, and engineering R&D services to government and commercial clients, with deep health and biomedical research offerings. Comparable in scale, funding mix (federal grants/contracts), and program operations role.
- Walter Reed Army Institute of Research (WRAIR): Core HJF partner and a DoD biomedical research laboratory conducting infectious disease, vaccine, and combat casualty care research. Directly comparable in mission and research focus; HJF often operates as the administrative backbone for WRAIR investigators.
- PATH: Global nonprofit focused on health innovation, vaccine and diagnostic development, and technology transfer. Closely mirrors HJF's nonprofit R&D, technology licensing, and global health footprint, though with greater emphasis on low-resource settings.
- AAHI (formerly Infectious Disease Research Institute): Nonprofit biotech developing vaccines and immune-based therapies for infectious diseases, including adjuvant and formulation platforms. Directly comparable in vaccine/therapeutic R&D focus, scale, and nonprofit structure.
Broad incumbents
- MITRE Corporation: Federally funded R&D center (FFRDC) operator with deep defense and health portfolios; while broader than HJF, MITRE offers a useful structural parallel as a nonprofit running mission-critical government research programs at scale.
- RAND Corporation: Nonprofit research institution with established defense, health, and policy research practices serving federal sponsors. Shares the nonprofit/government-funded operating model, although its core focus is policy analysis rather than wet-lab science.
- Biomedical Advanced Research and Development Authority (BARDA): U.S. federal authority that funds advanced development of medical countermeasures. While government rather than nonprofit, BARDA addresses the same translational medical R&D mission and competes for similar DoD/HHS research dollars.
- Coalition for Epidemic Preparedness Innovations (CEPI): Global partnership funding vaccine development against epidemic threats; a peer in vaccine R&D funding and coordination, with overlap on cross-sarbecovirus and pan-coronavirus vaccine interests relevant to HJF's portfolio.
- National Center for Advancing Translational Sciences (NCATS): NIH center focused on translational science and moving discoveries from bench to clinic. Adjacent peer given shared translational/clinical development interests and federal alignment, though federally funded rather than nonprofit.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat6 records
Key risks5 records
Key highlights6 records
Customer concentration
Henry M. Jackson Foundation social profiles
Digital presenceHenry M. Jackson Foundation financial estimates
Financial estimateRevenue estimate
Valuation estimate
Henry M. Jackson Foundation leadership team
Management profileNumber of profiles
Profiles3 records
Henry M. Jackson Foundation funding detail
Funding detailFunding overview
Funding rounds3 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Henry M. Jackson Foundation M&A and investment
M&A and investmentM&A1 record
Investments2 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Henry M. Jackson Foundation
What does Henry M. Jackson Foundation do?
HJF provides scientific, administrative, and program operations services to enable military medical researchers and clinicians to make discoveries, including proposal support, program operations, regulatory compliance, research administration, and research staffing. It also develops and licenses proprietary medical innovations — vaccines, therapeutics, diagnostics, biomarkers, and clinical decision support tools — generated through its military medical research collaborations, and operates a regional biotech incubator for dual-use startups.
Is Henry M. Jackson Foundation a public or private company?
Henry M. Jackson Foundation is a private company. It is classified as nonprofit foundation owned and is currently operating.
When was Henry M. Jackson Foundation founded?
Henry M. Jackson Foundation was founded in 1983. It employs 1,001 to 5,000 people.
Where is Henry M. Jackson Foundation based?
Henry M. Jackson Foundation is headquartered in Bethesda, United States, in the North America region.
How does Henry M. Jackson Foundation make money?
Two revenue lines are on record. Research Support Services are the primary driver. The others are technology Licensing.
Who are Henry M. Jackson Foundation's main competitors?
Direct peers on record are Battelle Memorial Institute, RTI International, Walter Reed Army Institute of Research (WRAIR), PATH and AAHI (formerly Infectious Disease Research Institute). Broad incumbents are MITRE Corporation, RAND Corporation, Biomedical Advanced Research and Development Authority (BARDA), Coalition for Epidemic Preparedness Innovations (CEPI) and National Center for Advancing Translational Sciences (NCATS).
Does Henry M. Jackson Foundation have an API?
No public API is recorded for Henry M. Jackson Foundation.
What industry is Henry M. Jackson Foundation in?
Henry M. Jackson Foundation's product category is Military Medical Research Services. Its primary akta.pro industry code is BPAIAHAC, Defense R&D, Test, Evaluation & Innovation, with a secondary code of HLACAMAL, Lab Data Exchange & Interoperability (HL7/FHIR/LDT Results Delivery). Its NAICS code is 5417 and its SIC code is 8731.